Article ID Journal Published Year Pages File Type
8447421 European Journal of Cancer 2011 6 Pages PDF
Abstract
Although this study was retrospective, a 1M-RDI cut-off value of ⩾50% for sorafenib may be the first factor to predict PFS but not OS in cytokine pretreated mRCC patients. The data indicate that a dose of 400 mg/day of sorafenib administered successively for the first one month was necessary to prolong disease stabilisation and could be tolerated by Japanese patients.
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Authors
, , , , , , , , , , , , , , ,